Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

Recruiting now · Phase 4

Conditions studied: Psoriasis

In brief

The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive efficacy would lead to a more personalized approach for psoriasis treatment. To do this, the investigators will be asking participants to try two different already on the market FDA-approved psoriasis drugs for 8 weeks at a time. The investigators will be monitoring participants skin for improvements as well as taking blood and skin samples at least three times. Investigators may also ask to take stool samples and/or skin swabs.

Key facts

Study ID

NCT05270733

Run by

University Hospitals Cleveland Medical Center

People needed

56

Starts

2022-11-10

Expected to finish

2026-12-31

Last updated by the study team

2026-04-02

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with plaque-type psoriasis defined by either:
• A board-certified dermatologist, OR
• Dermatology Nurse Practitioner, OR
• Skin punch biopsy
• Insurance that includes an anti-p40 biologic (ustekinumab/.Stelara) and at least one anti-p19 biologic (guselkumab/Tremfya or risankizumab/Skyrizi)
• Must be naive to ustekinumab, guselkumab, and risankizumab.
• Involvement of body surface area (BSA) of at least 10% at screening and baseline visit.
• Able to give informed consent under IRB approval procedures

You may not qualify if…

• Pregnant, breastfeeding, or planning to get pregnant 8 weeks before, during, and 8 weeks after the study.
• Inability to provide informed consent
• Inability to secure ustekinumab and either gusekumab or risankizumab for use while on trial
• Use of tanning booths for at least 4 weeks prior to baseline visit
• Current or recent use of topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 2 weeks prior to baseline visit and for duration of trial
• Current or recent use of systemic or biologic therapy for at least 8 weeks prior to baseline visit
• Patients with psoriatic arthritis or other rheumatologic diseases (e.g., Crohn's disease).

Where it is running

• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.